by Truveta Staff | Sep 22, 2023 | Technology
Epilepsy is a complex neurological disorder, characterized by recurrent, unpredictable seizures. The fourth most common neurological disorder in the world, an estimated 3.4 million (3M adults and 470,000 children) have active epilepsy in the US. These seizures...
by Truveta Staff | Jan 10, 2023 | Technology
The key to any disease study is rich data. We recently met with the CEO of a biotech company that specializes in the development of immunotherapies. He and his team had tried to recruit patients for a series of clinical trials related to several rare disease...
by Terry Myerson, CEO | Nov 2, 2022 | News
In just over two years — with amazing teamwork across Truveta and our 25 health system members, and strategic partnerships with customers like Pfizer and Boston Scientific — it is so exciting to announce the availability of Truveta Studio. It is amazing...
